From 'Untreatable' to 'Early Diagnosis and Intervention': How Alzheimer's Disease Public Education Is Driving Societal Awareness Transformation

On March 22, 2026, an Alzheimer's disease science communication creative contest themed "Rushing Early to Keep Memories Safe" concluded with a grand award ceremony at Tsinghua University. Hosted by Eli Lilly and organized by Tsinghua University, the event brought together nearly 200 young creators from over 30 academic institutions and more than 40 senior citizens for intergenerational collaboration. From nearly 100 projects, 45 outstanding science communication works were selected. At the award ceremony, the young creators utilized diverse formats such as videos, graphics, texts, and interactive designs to transform complex medical knowledge into warm and engaging expressions, bringing Alzheimer's disease—a long-misunderstood condition—into the public eye in a new way.

However, the significance of this competition goes far beyond an awards ceremony. Currently, among China's population aged 60 and above, the prevalence rate of Alzheimer’s disease has reached 3.9%. However, due to misconceptions and the stigma associated with the disease, most patients are only identified after exhibiting significant memory and cognitive issues, missing the optimal window for intervention. Some patients, even after diagnosis, give up on treatment because of the mistaken belief that the condition is "incurable," leading to continued progression of the disease.

This reveals a deep contradiction: scientific progress has moved Alzheimer's disease from "irreversible despair" to "intervenable hope." The availability of novel specific biomarkers allows the disease to be accurately diagnosed earlier, even while memory and cognitive functions remain intact. However, public awareness lags far behind scientific advancements. How to transform the medical concept of "early identification, early diagnosis, and early treatment" into social consensus and everyday action is the core proposition this competition seeks to address.

"The First Line of Defense" for Alzheimer's prevention and treatment does not lie in hospitals but within families and communities. Wu Qi, deputy editor-in-chief of *Life Week*, pointed out the crux during a roundtable discussion: "The early symptoms of Alzheimer’s are subtle, making it hard for patients and their families to detect signs early on or distinguish between normal aging and illness." This ambiguity allows the disease to quietly progress for several years before being identified. By the time it reaches the middle or late stages, the patient's cognitive and daily living abilities have severely declined, leaving families and society burdened with the heavy, long-term pressure of caregiving.

Health science communicator Li Zhizhong (pen name "Bolo") also pointed out that many people fear or passively respond to Alzheimer's disease due to deeply ingrained misconceptions such as "there is no cure." This cognitive misunderstanding directly leads to delays in action—some patients, even after diagnosis, believe there are no effective treatments and thus give up on treatment. Therefore, the real challenge in Alzheimer's prevention and treatment lies not in the technical question of "whether it can be treated," but in the cognitive issue of "whether one is willing to face it and whether it can be detected early."

The outstanding highlight of this science popularization creative contest lies in its choice of a path completely different from traditional health communication—not imposing knowledge on the public from an authoritative stance, but rather entering public life from an empathetic perspective. Traditional science popularization models often focus on listing knowledge points while ignoring the "emotional gap" that must be bridged for knowledge to translate into action. Only when science popularization works can make people "understand, remember, and be willing to share," can scientific knowledge truly break out of professional circles and enter the public's daily cognition.

Hang Min, Deputy Dean of the School of Journalism and Communication at Tsinghua University, emphasized: "Transforming professional and complex medical knowledge into information that the public can understand, are willing to pay attention to, and take action on is an important issue in public health communication." This shift from "knowledge transmission" to "emotional resonance" is a critical step in the societal cognitive transformation regarding Alzheimer's disease.

If science popularization is the "catalyst" for changing cognition, then the advancement of science and the collaboration of society form the foundation for making all of this possible. In recent years, the field of Alzheimer's disease has witnessed a "once-in-a-generation" turning point. Carole Ho, Executive Vice President of Eli Lilly and Company and President of its Neuroscience Division, pointed out that thanks to the availability of new specific biomarkers, Alzheimer’s disease can now be diagnosed earlier and more accurately before memory and cognitive functions are impaired. She also emphasized that young creators, through insightful and empathetic expression, can transform complex medical knowledge into easily understandable content, driving the concept of "early identification, early diagnosis, and early treatment" into action and helping more patients seize the precious window for treatment.

Eli Lilly and Company Vice President and China General Manager De Herland emphasized that innovative drugs bring hope to Alzheimer's patients, and reducing the overall burden of this disease on society requires joint efforts from all sectors of the healthcare system to ensure that patients have access to treatment opportunities at an earlier stage of the disease, when treatment is most likely to be beneficial.

As a global pharmaceutical leader with nearly 40 years of dedication to the Alzheimer's disease field, Eli Lilly and Company has invested a cumulative total of $11 billion in the research and development of innovative therapies and diagnostic technologies for Alzheimer’s disease, with over 20,000 patients worldwide participating in its clinical trials. Wang Li, Senior Vice President of Eli Lilly and Company and Head of the Drug Development and Medical Affairs Center at Eli Lilly China, stated during a roundtable forum: "Tackling Alzheimer’s disease is an undeniable responsibility for Eli Lilly. The investment in drug R&D for this disease is substantial, the cycle is long, and the challenges are immense, but we have never shied away. Continuous exploration in R&D has brought new possibilities for patients to maintain their quality of life and slow the progression of the disease."

To better address the challenges of Alzheimer's disease, it requires not only continuous efforts from companies to overcome R&D difficulties but also the collaborative work of all sectors of society to enhance public awareness, ensuring early diagnosis and treatment truly take root and seizing the precious treatment window. From corporate R&D to university outreach, from media dissemination to youth creativity, from clinical diagnosis and treatment to community care — only when these forces come together can we truly bridge the "last mile" from scientific breakthroughs to societal action.

The prevention and treatment of Alzheimer's disease is not a sprint, but a marathon. It requires continuous scientific breakthroughs, the constant improvement of the healthcare system, and, more importantly, a deep transformation in societal awareness. The successful conclusion of this science popularization creative competition marks a powerful leg in this marathon—it allows us to see that although the change in awareness is slow, it is happening; though the power of action may be small, it is gathering momentum. On this "Memory Road," every person’s participation is a step toward safeguarding the future.